ProtoKinetix, Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PKTX research report →
Price Chart
About the company
ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia.
- CEO
- Michael Richard Guzzetta
- IPO
- 2002
- Employees
- 5
- HQ
- Dalton, OH, US
Get TickerSpark's AI analysis on PKTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $78.32K
- P/E
- -0.67
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- -0.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -101.62%
- ROIC
- -61.23%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $0
- Net Income
- $0+100.0%
- EPS
- $0.00+100.0%
- OCF Growth
- +39.3%
- FCF Growth
- +39.3%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.73
- RSI (14)
- 46
- Avg Volume
- 26.80K
No earnings-call transcripts are available for PKTX yet.
- Free Float
- 62.3%
- Shares Outstanding
- 411.63M
- Float Shares
- 244.02M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Williams Jones Wealth Management, LLC. | 20.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Lamp Jason G. | other | 0 |
| Jun 17, 26 | Brunt Keith R. | other | 0 |
| Jun 17, 26 | Brunt Keith R. | other | 0 |
| Jun 17, 26 | Brunt Keith R. | other | 2,750,000 |
| Jun 17, 26 | Jones Michael Winston | other | 0 |
| Sep 26, 24 | SMITH CLARENCE EDWARD | buy | 2,000,000 |
| Jun 14, 24 | SMITH CLARENCE EDWARD | buy | 3,100,000 |
| Jun 13, 24 | SMITH CLARENCE EDWARD | buy | 3,400,000 |
| Mar 29, 24 | SMITH CLARENCE EDWARD | buy | 2,500,000 |
| Mar 20, 24 | SMITH CLARENCE EDWARD | buy | 666,667 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PKTX coverage
Recent articles, reports, and earnings notes.
No research on PKTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PKTX report →ProtoKinetix (OTCMKTS:PKTX) Shares Pass Below 50-Day Moving Average – Here’s What Happened
defenseworld.net · Jan 10
ProtoKinetix (OTCMKTS:PKTX) Shares Pass Below 50-Day Moving Average – Here’s What Happened
defenseworld.net · Dec 3
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
businesswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.